GLP1R and type 2 diabetes mellitus: Hence, there are consistent data supporting use of incretin-based therapies, particularly GLP-1 RAs, in socioeconomically disadvantaged people with type 2 diabetes, considering that such individuals are at increased risk for developing cardiovascular complications [2].